Concepedia

Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma

Takafumi Kuroda, Hideaki Ogiwara, Mariko Sasaki, Kazuaki Takahashi, Hiroshi Yoshida, Takako Kiyokawa, Kazuki Sudo, Kenji Tamura, Tomoyasu Kato, Aikou Okamoto,

Gynecologic Oncology · 2019 · 33 citations · 34 references

DOIFull text

Open access

Abstract

ARID1A-deficient OCCC patients could benefit from gemcitabine treatment in clinical settings.

References

34

Integrated genomic analyses of ovarian carcinoma

Debra Bell, Andrew Berchuck, Wendy Winckler · Nature · 2011 · 8K citations · Full text

, , +3

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

Christina Fitzmaurice, Christine A. Allen, Ryan M Barber et al. · JAMA Oncology · 2016 · 6.2K citations · Full text

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

, , +10

<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas

Kimberly C. Wiegand, Sohrab P. Shah, Osama M. Al‐Agha et al. · New England Journal of Medicine · 2010 · 1.6K citations · Full text